If you're taking or considering Ozempic, Wegovy, Mounjaro, or Zepbound, you may have come across warnings about gallbladder problems. It's a real, documented finding from the clinical trial data — not a rumor — but the risk is smaller and better understood than it might sound, and it largely tracks a pattern seen with any form of rapid weight loss.
This article is for general education and is not medical advice. It does not diagnose or treat any condition. Talk to your doctor or pharmacist about your personal risk factors and any symptoms you're experiencing before making decisions about your medication.
What the Trial Data Actually Shows
In the STEP 1 trial, a 68-week randomized, placebo-controlled study of once-weekly semaglutide 2.4 mg in 1,961 adults with overweight or obesity, gallbladder-related disorders (mostly gallstones) were reported in about 2.6% of the semaglutide group compared with 1.2% of the placebo group (Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021).
A similar pattern showed up in SURMOUNT-1, the 72-week trial of tirzepatide in 2,539 adults with obesity or overweight — cholecystitis and cholelithiasis were reported more often in the tirzepatide groups than on placebo (Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022). Exact incidence figures have varied slightly across different published summaries of that trial's safety data, but the direction — more gallbladder events on drug than placebo — is consistent.
Why This Happens: It's Mostly About the Weight Loss, Not the Drug
Rapid weight loss changes the composition of bile and can slow gallbladder motility, both of which favor gallstone formation. This is a well-documented pattern seen with bariatric surgery and very-low-calorie diets, not something unique to GLP-1 medications — people who lose weight quickly by any method carry a higher gallstone risk than people who lose weight gradually.
Because semaglutide and tirzepatide can produce substantial, relatively fast weight loss for many people, some of the excess gallbladder risk in the trials likely reflects that pace of change rather than a separate drug effect on the gallbladder itself.
Warning Signs to Take Seriously
| Symptom | What It Can Indicate | Action |
|---|---|---|
| Persistent upper-right abdominal pain | Gallstones or gallbladder inflammation | Contact your doctor promptly |
| Pain radiating to back or right shoulder | Classic biliary colic pattern | Contact your doctor promptly |
| Fever with abdominal pain | Possible gallbladder infection (cholecystitis) | Seek care same day |
| Yellowing of skin or eyes (jaundice) | Possible bile duct obstruction | Seek care same day |
Severe abdominal pain that doesn't ease, especially with fever, vomiting, or jaundice, warrants prompt medical evaluation — these can be signs of a gallbladder infection or a blocked bile duct, which sometimes require urgent treatment.
Can You Lower Your Risk?
Slower, more gradual weight loss is generally associated with lower gallstone risk than very rapid weight loss, a pattern seen across weight-loss methods generally, though individual risk factors — family history, sex, prior gallstones, and rate of weight change — also play a role. If you're concerned, talk to your prescriber about your dose-escalation pace and whether a slower titration schedule makes sense for you. Do not adjust your dose on your own.